SLC5A2 and chronic kidney disease: The patients treated with ipragliflozin showed a significant reduction in proteinuria compared with those not treated with this SGLT2 inhibitor only in a small subgroup complicated by CKD (defined as a UACR ≥ 30 mg/g and/or UPCR ≥ 0.5 g/g and/or eGFR < 60 mL/min/1.73 m2).